Relmada Therapeutics, Inc. (RLMD)

Market Cap	120.70M
Revenue (ttm)	n/a
Net Income (ttm)	-98.79M
Shares Out	30.17M
EPS (ttm)	-3.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,601
Open	4.300
Previous Close	4.300
Day's Range	3.950 - 4.314
52-Week Range	2.360 - 7.223
Beta	0.19
Analysts	Strong Buy
Price Target	26.00 (+550.0%)
Earnings Date	May 9, 2024

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD

Analyst Forecast

According to one analyst, the rating for RLMD stock is "Strong Buy" and the 12-month stock price forecast is $26.0.

Price Target

$26.0

(550.00% upside)

Analyst Consensus: Strong Buy